WILMINGTON, N.C., Jan. 23 /PRNewswire-FirstCall/ -- PPD, Inc. (Nasdaq: PPDI) today announced that it has expanded its global central lab services into China through an exclusive agreement with Peking Union Lawke Biomedical Development Limited (PUL). The agreement allows PPD to begin immediately providing biopharmaceutical clients with its full range of highly customized central lab services in China.
"Chinese law makes it extremely difficult to export lab samples to other countries for testing," said Agostino L. Fede, Ph.D., senior vice president of PPD and head of PPD's global central labs. "Our agreement with PUL expands our global central lab capabilities in a high growth clinical research market. It also saves our clients time and money by providing lab results more quickly without incurring expenses for exporting shipments."
Under the terms of the agreement, PPD invested in laboratory equipment located at Peking Union Medical College in the Beijing Zhong Guan Cun Life Sciences Park, the largest life sciences park in China. The equipment is identical to platforms located at PPD's global central labs in Brussels, Belgium, and Highland Heights, Ky., and assays performed have been extensively cross validated and precisely calibrated to match instruments at these labs. With these and other ongoing quality assurance measures, PUL and PPD deliver laboratory data that are directly combinable. In addition, PUL is interfaced real-time to ConneXion, PPD's proprietary computer system, to assure consistent management and reporting.
Jian Ho, M.D., Ph.D., medical director at PUL, will oversee the lab
while PPD will lead project management and investigator services and work
with clients on study setup. As part of the agreement, PUL will conduct
chemistry, hematology, urinalysis and hemoglobin A1c tests to support PPD's
clinical trials business in China. PUL also offers an extensive range of
esoteric tests. In return, PUL will have rights to use the
|SOURCE PPD, Inc.|
Copyright©2008 PR Newswire.
All rights reserved